Date: 2015-03-31
Type of information: Collaboration agreement
Compound: cardiovascular genomics
Company: Broad Institute of MIT and Harvard (USA - MA) Bayer Healthcare (Germany)
Therapeutic area: Cardiovascular diseases
Type agreement: collaboration R&D
Action mechanism:
Disease: cardiovascular diseases
Details: * On March 31st, 2015, the Broad Institute of MIT and Harvard have expanded their collaboration with Bayer HealthCare to include cardiovascular genomics and drug discovery. The goal of this new part of the alliance is to leverage insights from human genetics to help create new cardiovascular therapies. As part of this alliance, Broad Institute and Bayer HealthCare will collaborate on genetic discovery, target validation, and drug discovery activities. Governance for this alliance will be comprised of a joint steering committee and joint research committee that will oversee research progress and direction. Financial terms of the agreement were not disclosed.
Financial terms:
Latest news:
